Vertex to acquire Crinetics Pharmaceuticals for $85.00 per share in cash; expected close Q3 2026

VERTEX PHARMACEUTICALS INC / MA

Vertex to acquire Crinetics for $85.00 per share in cash; expected to close in Q3 2026.
$4.5B bridge loan facility from Bank of America and Morgan Stanley backs the deal; no financing condition.
Crinetics stockholders must approve; HSR and foreign regulatory clearances required; termination fee of $350M.
Vertex expects deal to accelerate revenue growth, with potential >$5B annual revenue; accretive to non-GAAP op income by 2029.
Crinetics' pipeline includes PALSONIFY (acromegaly) and atumelnant (CAH); Vertex sees significant commercial potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.